Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection
Under the multiyear strategic partnership Anumana will conduct a clinical-validation trial and seek FDA De Novo classification for the algorithm.

Under the multiyear strategic partnership Anumana will conduct a clinical-validation trial and seek FDA De Novo classification for the algorithm.

Go to Source
2022-12-15 23:17